THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE
The prevalence of congestive heart failure (CHF) is growing further with age, and 65% of the sufferers are in the age group from 65 to 80 y.o. Despite success in CHF treatment, mean year mortality is about 6%, and mortality of those with clinically salient CHF reaches 12%. To increase duration of li...
Saved in:
Main Author: | A. B. Khadzegova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2014-09-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/152 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01) -
RATIONAL CHOICE OF Β-ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY
by: M. L. Maximov
Published: (2015-12-01) -
URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01) -
Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01) -
Modern views on β-adrenoblocker therapy in elderly patients with chronic heart failure
by: E. V. Privalova
Published: (2007-06-01)